PFE USUSD26.04▲ +0.35 +1.36%
O --H 26.21L 25.79Prev 25.69Vol 31.8M52W 23.08 - 28.75Mkt $148.07BP/E 19.1NYSEPharmaceutical PreparationsCIK 0000078003
Price · 1Y
+11.5% 12M
AI Research Brief
fetching fundamentals & filings
Key Statistics
FY2025
Mkt cap
$148.07B
P/E
19.1
P/S
2.4
Rev growth
-1.6%
Gross mgn
74.3%
Op margin
--
Net margin
12.4%
ROE
9.0%
ROA
3.7%
Debt/Eq
0.71
Trailing Return
1W
-0.5%
1M
-1.8%
3M
-3.7%
6M
+1.8%
1Y
·
YTD
+3.4%
23.08
28.7552W
Financial History
value · YoY heat
| Metric | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Revenue | $41.65B | $81.29B | $101.17B | $59.55B | $63.63B | $62.58B |
| Gross profit | $33.17B | $50.47B | $66.83B | $34.60B | $45.78B | $46.51B |
| Operating income | · | · | · | · | · | · |
| Net income | $9.16B | $21.98B | $31.37B | $2.12B | $8.03B | $7.77B |
| Gross margin | 79.6% | 62.1% | 66.1% | 58.1% | 71.9% | 74.3% |
| Operating margin | · | · | · | · | · | · |
| Net margin | 22.0% | 27.0% | 31.0% | 3.6% | 12.6% | 12.4% |
Fundamentals
Dec 31, 2025
- Revenue
- $62.58B
- Gross profit
- $46.51B
- Operating income
- --
- Net income
- $7.77B
- Diluted EPS
- 1.36
- Total assets
- $208.16B
- Total liabilities
- $121.39B
- Shareholders' equity
- $86.78B
- Cash & equivalents
- $1.14B
- Long-term debt
- $61.64B
- Shares outstanding
- 5,686,267,431
Comparable Companies
Relative Valuation
reading the comps
Analyst Ratings
Ownership
Earnings Call
locating latest call
News
Catalysts & Events
Filings
Sources & As-Of
- SEC EDGAR — XBRL companyfactsDec 31, 2025
- SEC EDGAR — submissionsMay 5, 2026
- Yahoo Finance (price)Jun 5, 2026
Assembled Jun 8, 2026 · public data, may be delayed or incomplete · verify against primary filings · not advice